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Abstract 46 
 47 
Objectives: Triaging patients with suspected high blood pressure for ambulatory blood pressure monitoring 48 
(ABPM), on the basis of their clinic blood pressure and characteristics, may reduce the need for ABPM. This 49 
study aimed to prospectively validate this new approach using data from routine practice. 50 
Design: Prospective observational cohort study. 51 
Setting: Ten primary care practices and one hospital in the UK.  52 
Participants: Consecutive patients aged >18 years referred for ABPM in routine practice. 53 
Interventions: All patients underwent ABPM and had the new triage algorithm (PROOF-BP) applied.  54 
Main outcome measures: Proportion correctly classified with hypertension using the triaging strategy 55 
compared to the reference standard of daytime ABPM. Sensitivity, specificity and area under the receiver 56 
operator characteristic curve (AUROC) for detecting hypertension. 57 
Results: A total of 887 patients (mean age 52.8±16.2 years) were referred for ABPM and enrolled during the 58 
study period. The triaging strategy correctly classified hypertensive status in 801 patients (90%, 95% CI 88% 59 
to 92%) and had a sensitivity of 97% (95% CI 96% to 99%) and specificity of 76% (95% CI 71% to 81%) 60 
for hypertension. The AUROC was 0.86 (95% CI 0.84 to 0.89). Use of triaging, rather than uniform referral 61 
for ABPM in routine practice would have resulted in 435 patients (49%, 95% CI 46% to 52%) being referred 62 
for ABPM and the remainder managed on the basis of their clinic measurements. Of these, 69 (8%, 95% CI 63 
6% to 10%) would have received treatment that would have been deemed unnecessary had they received 64 
ABPM.  65 
Conclusions: In a population of patients referred for ABPM, this new triaging approach accurately classified 66 
hypertensive status for most, with half the utilisation of ABPM compared with usual care. This triaging 67 
strategy can therefore be recommended for diagnosis or management of hypertension in patients where 68 
ABPM is being considered, particularly in settings where resources may be limited. 69 
 70 
Word count: 305 words 71 
 72 
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Print abstract 75 
 76 
Study question: What is the accuracy of triaging patients for ambulatory blood pressure monitoring 77 
(ABPM) in routine clinical practice? 78 
Methods: This study used a prospective observational cohort design, recruiting patients from ten primary 79 
care practices and one hospital in the UK. Consecutive patients aged >18 years referred for ABPM in routine 80 
practice were enrolled. All paeticipants underwent ABPM and had the new triage algorithm (PROOF-BP) 81 
applied. The proportion correctly classified with hypertension using the triaging strategy was estimated and 82 
compared to the reference standard of daytime ABPM. Secondary outcomes included sensitivity, specificity 83 
and area under the receiver operator characteristic curve (AUROC) for detecting hypertension. 84 
Study answer and limitations: In a population of 887 patients referred for ABPM, the new triaging 85 
approach accurately classified hypertensive status in 801 patients (90%, 95% CI 88% to 92%) and had a 86 
sensitivity of 97% (95% CI 96% to 99%) and specificity of 76% (95% CI 71% to 81%) for hypertension. 87 
Use of triaging, rather than uniform referral for ABPM in routine practice would have resulted in 435 88 
patients (49%, 95% CI 46% to 52%) being referred for ABPM and the remainder managed on the basis of 89 
their clinic measurements. Of these, 69 (8%, 95% CI 6% to 10%) would have received treatment that would 90 
have been deemed unnecessary had they received ABPM.  91 
What this study adds: The new triaging strategy accurately classified an individual’s hypertensive status 92 
with half the utilisation of ABPM compared with usual care. It can therefore be recommended for diagnosis 93 
or management of hypertension in patients where ABPM is being considered, particularly in settings where 94 
resources may be limited. 95 
Funding, competing interests, data sharing: This work was funded by a Medical Research Council 96 
Fellowship (MR/K022032/1). Authors declare no other conflicts of interest. Patient level data are available 97 
upon request. 98 
 99 
Word count: 298 100 
 101 
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Article Summary 103 
What is already known on this subject 104 
 105 
 Daytime ambulatory blood pressure monitoring (ABPM) is the gold standard method for measuring 106 
blood pressure and diagnosing hypertension. 107 
 ABPM is currently recommended for all patients with raised screening clinic pressure, but triaging 108 
patients for this additional monitoring may be a more effective strategy. 109 
 The PRedicting Out-of-OFfice Blood Pressure (PROOF-BP) algorithm can be used to triage for 110 
ABPM and appears cost-effective when studied using carefully measured blood pressure readings 111 
from previous research studies. 112 
 Blood pressure readings taken in research studies are not always comparable to those taken in 113 
clinical practice where there may be suboptimal measurement technique and rounding bias. 114 
 115 
What this article adds 116 
 117 
 This is the first prospective, external validation of an algorithm for triaging patients for ABPM using 118 
data collected in a clinical practice setting. 119 
 This triaging strategy accurately classified an individual’s hypertensive status with half the 120 
utilisation of ABPM compared with usual care.  121 
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Introduction 122 
High blood pressure (hypertension) is an important risk factor for cardiovascular disease,(1) the leading 123 
cause of morbidity and mortality worldwide.(2) Hypertension can be managed effectively with 124 
antihypertensive medications.(3) Ambulatory blood pressure monitoring (ABPM) is the reference standard 125 
for confirming a diagnosis of hypertension, and is now commonly used prior to initiation of treatment.(3) 126 
This is because ambulatory blood pressure (BP), compared to clinic blood pressure, has been shown to 127 
estimate mean blood pressure more accurately and correlate better with a range of cardiovascular 128 
outcomes.(4-6) Indeed, clinic blood pressure often misclassifies true mean blood pressure due to white coat 129 
hypertension (high clinic blood pressure with normal ambulatory BP) or the converse, masked hypertension 130 
(high ambulatory BP with normal clinic blood pressure) (eFigure 1).(7-9)  131 
 132 
Current strategies for the diagnosis of hypertension recommended by the UK National Institute for Health 133 
and Care Excellence (NICE)(10) and the American College of Cardiology/American Heart Association Task 134 
Force(11) state that individuals should undergo out-of-office measurement (ambulatory or home BP 135 
monitoring) if blood pressure is raised in the clinic in order to confirm a diagnosis of hypertension. This 136 
method is cost-effective as it reduces misdiagnosis caused by white coat hypertension.(3) However, this 137 
approach is not perfect since in addition to detecting white coat hypertension, it results in other patients with 138 
true underlying hypertension identified by clinic blood pressure readings being sent for unnecessary out-of-139 
office monitoring. Additionally it will not capture those patients with masked hypertension and is not 140 
currently used routinely in uncontrolled patients on treatment who may also be misclassified due to white 141 
coat or masked effects. 142 
 143 
It has been suggested that triaging patients for ABPM may improve management of hypertension by limiting 144 
the use of ABPM to those most likely to be misclassified by clinic blood pressure.(12) The most effective 145 
way to triage patients for ABPM has been debated,(13, 14) but recent work proposes an individualised 146 
triaging approach, PROOF-BP, using multiple clinic readings and patient characteristics (eFigures 2 and 147 
3).(12, 15)  148 
 149 
This approach has been validated(12) and appears to be cost-effective in a research setting,(16) but blood 150 
pressure measurements made under such controlled conditions are not necessarily comparable to BP readings 151 
in routine clinical practice.(17-19) Differences can occur due to suboptimal measurement techniques(20-22) 152 
and rounding bias (rounding off readings to the nearest zero value).(23, 24) Thus, a triaging approach shown 153 
to be accurate in a research setting, may not be as precise in routine clinical practice. This study enrolled 154 
patients being referred for ABPM in both Primary and Secondary Care and collected relevant data to 155 
prospectively validate this new triaging approach in routine clinical practice.  156 
 157 
Methods 158 
The protocol for this study has been published previously.(25) An extended methods and the pre-specified 159 
analysis plan are given in the online appendix. 160 
 161 
Study design 162 
This study used a prospective, multi-centre observational cohort design, recruiting patients from Primary and 163 
Secondary Care.  164 
 165 
Study participants and setting  166 
Consecutive patients attending participating centres in Primary or Secondary Care, for whom ABPM was 167 
considered appropriate, were enrolled between May 2015 and January 2017. Eligible patients were those 168 
undergoing ABPM as a result of routine blood pressure screening or monitoring in Primary Care or via 169 
referral to Secondary Care with suspected hypertension, newly diagnosed or treated hypertension, resistant 170 
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hypertension, secondary hypertension or other conditions requiring specialist advice. Anonymised data were 171 
collected on all patients fulfilling the eligibility criteria: 172 
 173 
Inclusion Criteria 174 
- Age 18 years or above 175 
- Attending clinical practice for routine ABPM  176 
 177 
Exclusion Criteria 178 
- Aged under 18 years old 179 
- Lack of availability of basic clinical information 180 
- Multiple clinic blood pressure readings not recorded (obtained on at least three occasions within the 181 
same visit)  182 
- Ambulatory blood pressure monitor not worn as instructed 183 
 184 
Procedures 185 
All participants underwent ABPM, clinic blood pressure measurement and collection of patient 186 
characteristics. Data collected for each participant are detailed in the protocol(25) and included: blood 187 
pressure measurements (values and measurement technique), previous treatment prescriptions, body mass 188 
index (BMI), smoking status and history of diabetes, chronic kidney disease, atrial fibrillation and 189 
cardiovascular disease. Antihypertensive medication changes made after ABPM were not recorded. All data 190 
were collected from electronic health records and entered directly onto the study database by trained staff at 191 
each data collection site. 192 
 193 
To capture as close to ‘routine’ blood pressures as possible, all participating sites were asked to measure 194 
clinic and ambulatory blood pressure but no specific protocol for measurement was suggested or 195 
recommended. ‘Routine blood pressure’ was defined as readings taken by the consulting healthcare 196 
professional as part of routine clinical practice.  197 
 198 
A minimum of three clinic readings taken at the time of referral for ABPM or at monitor fitting were 199 
required for inclusion in the study. It is acknowledged that this may not always reflect routine practice(26) 200 
(even though it is recommended in guidelines),(10) but the three blood pressure readings were necessary to 201 
permit validation of the triaging algorithm. Each site was offered a validated automated blood pressure 202 
monitoring device (Omron M10-IT, Omron Corporation, Kyoto, Japan) to assist with the collection of 203 
multiple clinic blood pressure readings, but were given the option to continue using their own monitor, so 204 
long as at least three readings were taken and recorded. To our knowledge, all readings were taken with the 205 
physician or nurse present in the room. ABPM was conducted using the practice/hospital’s own ambulatory 206 
monitor and fitted by a trained nurse or allied health professional. Some practices in Primary Care only 207 
collected daytime ambulatory pressures. Details of clinic and ambulatory blood pressure monitors used at 208 
each site are given in the online appendix (eTable 1, online appendix).  209 
 210 
The PROOF-BP triaging approach  211 
The triaging strategy applied an algorithm to three blood pressure readings taken at the clinic appointment, 212 
combined with information from an individual’s electronic health record: age, sex, BMI, hypertensive and 213 
treatment history and the presence of cardiovascular disease (eFigures 2 and 3, online appendix).(12) This 214 
algorithm identified three groups: those with definitively normal blood pressure, those with definitively high 215 
blood pressure and those requiring further investigation using ABPM (see extended methods in online 216 
appendix for detail).  217 
 218 
 219 
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Primary outcome 220 
The primary outcome of this study was the proportion correctly classified with hypertension using the 221 
triaging strategy compared to the reference standard of daytime ABPM (using a threshold for hypertension of 222 
≥135/85 mmHg).(10, 11, 27) This was defined as the proportion of patients with sustained hypertension (true 223 
positives), normotension (true negatives), white coat hypertension (false positives) and masked hypertension 224 
(false negatives).  225 
 226 
Secondary outcomes 227 
The sensitivity (for detecting hypertension in patients with the condition), specificity (for ruling out 228 
hypertension in those without the condition), positive and negative predictor values were estimated and 229 
compared to guideline strategies for measuring blood pressure from the UK,(10) US,(11) Europe,(27) 230 
Canada(28) and Japan(29) (eTable 2, online appendix).  Further secondary outcomes included accuracy of 231 
the triaging strategy in different sub-groups: setting (Primary vs. Secondary Care), age (<65 years vs. >65 232 
years), sex, smoking status (never/ex-smoker vs. current smoker), BMI (<30kg/m2 vs. >30kg/m2), previous 233 
history of hypertension, diabetes, chronic kidney disease and cardiovascular disease.  234 
 235 
Data analysis 236 
Descriptive statistics were used to describe the number of patients classified with sustained hypertension, 237 
white coat hypertension, normotension and masked hypertension with the triaging approach (the primary 238 
outcome) using daytime ABPM as the reference standard. These were used to calculate the sensitivity, 239 
specificity, positive and negative predictor values of the triaging approach and the total proportion of 240 
participants with correctly classified hypertensive status and proportion that would have been referred for 241 
ABPM.  242 
 243 
To examine model performance, a logistic regression model was constructed with true hypertension (defined 244 
by daytime ABPM) as the dependant outcome variable and classification using the triaging approach as the 245 
independent predictor variable. From this model the area under the receiver operating characteristic 246 
(AUROC) curve statistic was estimated. Further analyses were conducted examining the primary outcomes 247 
using different definitions of clinic and ambulatory blood pressure (see online appendix). 248 
 249 
Post-hoc analyses 250 
Post-hoc analyses were undertaken to examine performance of the PROOF-BP algorithm on its own (without 251 
additional ABPM) and this was compared to other blood pressure measurement strategies (employed without 252 
ABPM).10 11 30-32 Subgroup analyses of the sensitivity and specificity of the PROOF-BP triaging approach 253 
were undertaken and accompanied by one additional non pre-specified subgroup: patients in whom the 254 
treating clinician’s own monitor was used to measure clinic blood pressure vs. those where monitors were 255 
provided by the research team. 256 
 257 
All analyses were conducted using STATA version 13.1 (MP parallel edition, StataCorp, Texas, USA). 258 
Results are presented as means or proportions, with standard deviations or 95% confidence intervals, unless 259 
otherwise stated.  260 
 261 
Sample size 262 
Based on the original validation of the PROOF-BP prediction model,(12) accrual of data from at least 800 263 
patients was required for estimation of hypertensive status with an accuracy of ±1-3% (see eTable 3, online 264 
appendix).(25) A sample size of up to 1000 patients was specified to ensure that the pre-specified sub-group 265 
analysis could be adequately powered.  266 
 267 
 268 
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Patient and public involvement 269 
Patients with a history of hypertension were approached to discuss the study at the design phase of the 270 
project. In particular their opinions were sought on the methods of recruitment and patient facing study 271 
literature, prior to ethics and NHS R&D applications. 272 
 273 
Approvals 274 
Ethical approval for this study was obtained from the National Research Ethics Service Committee South 275 
Central – Oxford A (reference; 15/SC/0184), and site-specific R&D approval acquired from the relevant 276 
NHS trusts.  277 
 278 
Results 279 
Recruitment and baseline population 280 
Ten general practice surgeries and one hospital Trust participated in the study. A total of 897 patients 281 
attended participating sites for clinic and ABPM during the study period. In total, ten patients (1.1%) were 282 
ineligible. Reasons for exclusion were: missing blood pressure readings (8 patients 0.9%), aged under 18 283 
years (1 patient, 0.1%) and missing clinical information (1 patient, 0.1%) (Figure 1). All remaining patients 284 
(887 patients, 99%) were enrolled into the study and included in the primary analysis.  285 
 286 
Mean age was 52.8 ± 16.2 years, 54% were female and 14% were current smokers (table 1). Mean clinic 287 
blood pressure at referral for ABPM was 147/91 ± 19/13 mmHg. A small proportion had diabetes, chronic 288 
kidney disease and a history of cardiovascular disease. Approximately 70% had a history of hypertension 289 
and 61% of the total population were taking at least one antihypertensive medication. Patients attending 290 
Secondary Care were younger and had higher blood pressure, more co-morbidities and were taking more 291 
antihypertensive medications (table 1). Most patients were referred for ABPM due to suspected hypertension 292 
or uncontrolled blood pressure (eTable 4). 293 
 294 
Primary analysis 295 
The triaging strategy (algorithm used in combination with ABPM) predicted true blood pressure (true 296 
positives 66%, 95% CI 63% to 69%; true negatives 25%, 95% CI 22% to 27%) with a low error rate (false 297 
positives 8%, 95% CI 6% to 10%; false negatives 2%, 95% CI 1% to 3%) (table 2). The triaging strategy 298 
resulted in 49% (95% CI 46% to 52%) being referred for ABPM and the remainder managed on the basis of 299 
their clinic measurements. Of the latter, 69 (8%, 95% CI 6% to 10%) would have received treatment that 300 
would have been deemed unnecessary had they received an ABPM (table 2).  301 
 302 
Secondary analysis 303 
The triaging strategy had a sensitivity of 97% (95% CI 96% to 99%) and specificity of 76% (95% CI 71% to 304 
81%) and an AUROC of 0.86 (95% CI 0.84 to 0.89) for predicting true hypertension (table 3). It would have 305 
resulted in higher sensitivity and negative predictive values, but lower specificity and positive predictive 306 
values compared to other diagnostic strategies, had they been applied to this population (including that 307 
recommended in the UK (eTables 5 and 6, online appendix).  308 
 309 
The sensitivity of the triaging strategy was consistently high (95% to 100%) regardless of the setting, 310 
underlying prevalence of hypertension, subgroup population or clinic blood pressure monitor used (table 3 311 
and figure 2). Specificity was affected by the population, with values as low as 60% in patients with chronic 312 
kidney disease and as high as 85% in patients with no previous diagnosis of hypertension (figure 2). 313 
Hypertensive status was correctly classified in 87-91% of patients, regardless of the setting, patient 314 
characteristics, co-morbidities or history of hypertension and/or treatment (figure 3). However, a lower 315 
prevalence of hypertension with more individuals with intermediate blood pressures resulted in more 316 
referrals for ABPM in a Primary Care setting (59% vs. 42% [Secondary Care]) and in those patients with no 317 
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history of hypertension (62% vs. 44% [history of hypertension]) or antihypertensive prescription (56% vs. 318 
44% [existing prescription]) (figure 4). 319 
 320 
The triaging approach performed consistently well in terms of hypertensive classification and lower 321 
utilisation of ABPM, regardless of the number of clinic blood pressure readings or period of 24 hours used 322 
for ABPM readings (eTable 7). The approach did result in fewer patients being correctly classified according 323 
to night-time blood pressure (90.3% [primary analysis] vs. 87.5% [night-time readings]), reflecting the 324 
different diagnostic thresholds used to define night-time hypertension. The PROOF-BP algorithm 325 
performance was reduced when utilised without ABPM (i.e. not as a triaging tool) (eTable 8, online 326 
appendix).  327 
 328 
Discussion 329 
Summary findings 330 
This study aimed to prospectively validate a new approach to determine who should be offered ABPM for 331 
suspected or poor control of hypertension in real world settings. In a population being referred for ABPM, 332 
use of a triaging strategy was found to capture nearly all patients with hypertension whilst resulting in half 333 
the number of referrals for resource intensive ABPM compared to usual care. However, such a strategy 334 
would misclassify as hypertensive 1 in 4 of those without hypertension, potentially leading to unnecessary 335 
treatment. Used in a diagnostic situation in people without a prior diagnosis of hypertension, this 336 
misclassification of normotensive individuals was reduced to 1 in 7. These findings suggest the potential for 337 
diagnosing and managing hypertension using a triaging strategy to reduce the need for ABPM.  338 
 339 
Strength and weaknesses 340 
This study was conducted according to a pre-published, peer reviewed protocol with analyses undertaken in 341 
line with a pre-specified analysis plan. The study included 98.8% of patients attending routine practice 342 
during the study period, suggesting it is likely to be representative of the target population (those who have 343 
an indication for ABPM), and was sufficiently powered to examine key outcomes. 344 
 345 
Unlike the previous studies in which the PROOF-BP triaging algorithm has been previously validated,(12, 346 
30-33) the measurement of clinic blood pressure was not standardised in terms of requiring healthcare 347 
professionals to use certain monitors or conform to a specific measurement protocol. This was deliberate in 348 
an attempt to replicate readings taken in routine clinical practice where blood pressure measurement 349 
techniques can vary.(34) It is recognised that such readings may not truly reflect routine practice either, since 350 
healthcare professionals knew they were participating in a research study and validated monitors were 351 
provided to some sites to aid the capture of three consecutive clinic readings.(32) In total, six of the eleven 352 
participating sites used the validated clinic blood pressure monitors supplied by the research team but this 353 
had no impact on the performance of the triaging approach. 354 
 355 
The study included patients in whom the treating physician felt ABPM was appropriate. In the majority of 356 
cases this was due to suspected hypertension or apparently uncontrolled blood pressure (eTable 4, online 357 
appendix). This included patients with no history of hypertension (i.e. those referred for diagnosis) and those 358 
already prescribed blood pressure lowering medications (i.e. those referred for management of hypertension). 359 
The findings are therefore widely applicable to patients undergoing diagnosis and also those in whom the 360 
consulting physician is considering treatment intensification but is unsure if this is appropriate. Whilst 361 
additional monitoring is not recommended in those with normal blood pressure,(10, 11, 27) 22% of the 362 
present cohort had clinic readings below 140/90 mmHg prior to ABPM and 9% proved to have masked 363 
hypertension which is consistent with previous prevalence estimates.(35-37)  364 
 365 
 366 
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Comparison with other literature 367 
Few studies have previously identified an effective method for triaging patients for out-of-office blood 368 
pressure monitoring, and none have externally validated such a method using data from a ‘routine’ clinical 369 
setting. The original PROOF-BP derivation paper reported good performance of the algorithm when used in 370 
combination with ABPM, with a sensitivity of 96% and specificity of 87%. Viera et al.,(13) examined the 371 
optimal threshold for referral for out-of-office monitoring based on automated clinic blood pressure levels in 372 
patients with normal clinic pressure for detection of masked hypertension. They reported a sensitivity of 76% 373 
and specificity of 58% for a clinic blood pressure threshold of 120 mmHg systolic. In practice, such a 374 
threshold would have limited accuracy and efficiency, missing 1 in 4 hypertensive patients and resulting in a 375 
large number of patients being referred for ABPM. As such, they did not recommend this approach for use in 376 
routine clinical practice. The PROOF-BP triaging strategy examined here uses an individualised approach, 377 
taking into account a patient’s clinic blood pressure level, variability and underlying cardiovascular risk. It is 378 
an approach which maximises the accuracy of hypertensive classification whilst minimising ABPM use 379 
compared to usual care, which uses fixed thresholds for referral in all patients. 380 
 381 
Implications for clinical practice  382 
Use of a triaging approach would significantly reduce the proportion of individuals requiring ABPM at the 383 
expense of “over treating” a small proportion of individuals. The triaging algorithm performed consistently 384 
across sensitivity analyses and sub-group analyses. Because the triaging mechanism is based on thresholds of 385 
adjusted clinic blood pressure, scenarios where a greater number of individuals have blood pressures close to 386 
the diagnostic threshold for hypertension are likely to result in greater numbers of patients being referred for 387 
ABPM. The greater the use of ABPM, the more accurate the triaging strategy was (in patients with no 388 
history of hypertension the sensitivity was 95%, specificity was 85% but 61% were referred for ABPM). 389 
Where ABPM facilities are widely available, clinicians may therefore wish to consider additional use of 390 
ABPM, where the risk of misdiagnosis is great but an individual is not within the triaging range. This could 391 
include younger, lower risk individuals for whom a lifetime of treatment may have an impact on their quality 392 
of life. However, in low and middle income countries where resources might be more stretched, the PROOF-393 
BP triaging approach represents an alternative option which maximises the benefits of ABPM and targets 394 
those with the most to gain.  395 
 396 
These data suggest that the PROOF-BP triaging strategy may be used in both Primary and Secondary Care 397 
wherever ABPM is being considered to rule out white-coat hypertension. To facilitate uptake, the algorithm 398 
is freely available as a calculator online (https://sentry.phc.ox.ac.uk/proof-bp) and could be incorporated into 399 
clinic computer systems, smartphone blood pressure management apps and Bluetooth enabled monitors, 400 
providing GPs and hospital physicians with instant feedback and management recommendations in terms of 401 
referral or treatment. 402 
 403 
Conclusions 404 
This prospective, external validation study demonstrates the accuracy of the PROOF-BP algorithm as a tool 405 
for triaging patients for ABPM in ‘routine’ practice. Used in conjunction with ABPM, the algorithm 406 
identifies most truly hypertensive patients and results in half as many patients being referred for additional 407 
ABPM compared to usual care. However, it may lead to a small number of patients taking unnecessary 408 
treatment. Such an approach can now be recommended for use in both Primary and Secondary Care, 409 
wherever ABPM is being considered to rule out white-coat hypertension or masked hypertension.   410 
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Tables and figure legends 442 
Table 1. Baseline characteristics 443 
Characteristic All patients Primary Care 
Secondary 
Care 
Total population 887 354 533 
Age (mean ± SD, years) 52.8 ± 16.2 57.4 ± 16.2 49.8 ± 16.9  
Sex (% female) 477 (53.8%) 184 (52.0%) 293 (55.0%) 
Ethnicity       
 -         White (%) 637 (71.8%) 286 (80.8%) 351 (65.9%) 
 -         Black (%) 67 (7.6%) 16 (4.5%) 51 (9.6%) 
 -         South Asian (%) 114 (12.9%) 34 (9.6%) 80 (15.0%) 
 -         Other (%) 28 (3.2%) 2 (0.6%) 26 (4.9%) 
 -         Unknown (%) 41 (4.6%) 16 (4.5%) 41 (4.6%) 
Smoking status       
-         Current (%) 124 (14.0%) 55 (15.5%) 69 (13.0%) 
-         Ex-smoker (%) 205 (23.1%) 113 (31.9%) 92 (17.3%) 
-         Never smoked (%) 499 (56.3%) 181 (51.1%) 318 (59.7%) 
-         Unknown (%) 59 (6.7%) 5 (1.4%) 54 (10.1%) 
BMI (mean ± SD, kg/m2) 30.8 ± 8.1 30.3 ± 7.2 31.1 ± 8.6 
Diabetes (%) 116 (13.1%) 46 (13.0%) 70 (13.1%) 
Chronic Kidney Disease (stages 3-5) (%) 59 (6.7%) 20 (5.7%) 39 (7.3%) 
Atrial Fibrillation (%)* 28 (3.3%) 15 (4.3%) 13 (2.6%) 
Diagnosis of hypertension (%) 619 (69.8%) 141 (39.8%) 478 (89.7%) 
Cardiovascular medications*       
Type of medication    
 -         ACE inhibitor (%) 265 (30.1%) 51 (14.5%) 214 (40.4%) 
 -         Angiotensin II receptor blocker (%) 129 (14.6%) 24 (6.9%) 105 (19.8%) 
 -         Calcium channel blocker (%) 279 (31.6%) 52 (14.9%) 227 (42.8%) 
 -         Thiazide (%) 170 (19.3%) 24 (6.9%) 146 (27.5%) 
 -         Beta blocker (%) 138 (15.7%) 32 (9.1%) 106 (19.9%) 
 -         Alpha blocker (%) 92 (10.4%) 16 (4.6%) 76 (14.3%) 
 -         Other antihypertensive (%) 45 (5.1%) 4 (1.1%) 41 (7.7%) 
 -         Statin (%) 234 (26.7%) 114 (32.7%) 120 (22.7%) 
 -         Antiplatelet (%) 118 (13.4%) 47 (13.5%) 71 (13.4%) 
Number of antihypertensives    
- No antihypertensive medications 349 (39.4%) 239 (67.5%) 110 (20.6%) 
- 1 antihypertensive medication 217 (24.5%) 57 (16.1%) 160 (30.0%) 
- 2 antihypertensive medication 149 (16.8%) 36 (10.2%) 113 (21.2%) 
- 3 antihypertensive medication 102 (11.5%) 17 (4.8%) 85 (16.0%) 
- >4 antihypertensive medication 70 (7.9%) 5 (1.4%) 65 (12.2%) 
Medical history       
 -         Coronary Heart Disease (%) 59 (7.1%) 20 (5.7%) 39 (8.1%) 
 -         Stroke/Transient ischemic attack (%) 41 (4.9%) 15 (4.3%) 26 (5.3%) 
 -         Heart failure (%) 11 (1.3%) 0 (0%) 11 (2.2%) 
 -         Peripheral vascular disease (%) 12 (1.4%) 5 (1.4%) 7 (1.4%) 
Mean Clinic systolic BP (mean ± SD, mmHg) 146.7 ± 19.2 143.8 ± 17.5 148.7 ± 20.1 
Mean Clinic diastolic BP (mean ± SD, mmHg) 90.6 ± 12.5 89.3 ± 10.0 91.5 ± 13.8 
Mean Daytime systolic ABPM (mean ± SD, mmHg) 140.8 ± 16.8 140.2 ± 17.8 141.2 ± 16.2 
Mean Daytime diastolic ABPM (mean ± SD, mmHg) 83.4 ± 11.7 81.9 ± 11.6 85.3 ± 11.5 
Mean Nighttime systolic ABPM (mean ± SD, mmHg) 128.5 ± 19.5 125.1 ± 18.0 130.0 ± 18.8 
Mean Nighttime diastolic ABPM (mean ± SD, mmHg) 74.0 ± 12.0 70.7 ± 11.0 75.7 ± 11.8 
Mean 24hr systolic ABPM (mean ± SD, mmHg) 137.5 ± 17.0 135.0 ± 16.6 138.2 ± 16.1 
Mean 24hr diastolic ABPM (mean ± SD, mmHg) 81.4 ± 11.3 78.6 ± 10.9 83.0 ± 11.1 
Clinic hypertension at visit (1st reading) (%) 695 (78.4%) 268 (75.7%) 427 (80.1%) 
White coat hypertension at visit (1st reading)  (%) 173 (19.5%) 87 (24.6%) 86 (16.1%) 
Masked hypertension at visit (1st reading)  (%) 79 (8.9%) 36 (10.2%) 43 (8.1%) 
*Proportion in those with available data444 
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Table 2. Classification of patients and utilisation of ABPM using the triaging approach 
Population 
Total 
population 
(n, %) 
True positive  
(Sustained 
hypertensive)  
(n, %, 95% CI) 
True negative 
(normotensive)  
(n, %, 95% CI) 
False positive (white 
coat hypertensive)  
(n, %, 95% CI) 
False negative  
(masked hypertensive)  
(n, %, 95% CI) 
Correctly classified  
(n, %, 95% CI) 
Utilisation of ABPM  
(n, %, 95% CI) 
Overall 887 (100%) 584 (66%) (63% to 69%) 217 (24%) (22% to 27%) 69 (8%) (6% to 10%) 17 (2%) (1% to 3%) 801 (90%) (88% to 92%) 435 (49%) (46% to 52%) 
For diagnosis* 268 (30%) 156 (58%) (52% to 64%) 88 (33%) (27% to 39%) 16 (6%) (3% to 10%) 8 (3%) (1% to 6%) 244 (91%) (87% to 94%) 165 (62%) (55% to 67%) 
For management† 619 (70%) 428 (69%) (65% to 73%) 129 (21%) (18% to 24%) 53 (9%) (6% to 11%) 9 (1%) (0.7% to 3%) 557 (90%) (87% to 92%) 270 (44%) (40% to 48%) 
ABPM=ambulatory blood pressure monitoring 
*Patients without a previous history of hypertension 
†Patients with a previous history of hypertension 
 
 
Table 3. Accuracy of the triaging approach 
Population 
Total 
population 
AUROC  
(95% CI) 
Sensitivity  
(%, 95% CI) 
Specificity  
(%, 95% CI) 
Positive predictive value 
(%, 95% CI) 
Negative predictive 
value (%, 95% CI) 
Overall 887 (100%) 0.86 (0.84 to 0.89) 97.2% (95.9% to 98.2%) 75.9% (72.9% to 78.7%) 89.4% (87.2% to 91.4%) 92.7% (90.8% to 94.3%) 
For diagnosis* 268 (30%) 0.90 (0.86 to 0.94) 95.1% (91.8% to 97.4%) 84.6% (79.8% to 88.8%) 90.7% (86.5% to 93.9%) 91.7% (87.8% to 94.8%) 
For management† 619 (70%) 0.84 (0.81 to 0.88) 97.9% (96.4% to 98.9%) 70.9% (67.2% to 74.5%) 93.5% (91.3% to 95.3%) 89.0% (86.3% to 91.4%) 
AUROC=area under the receiver operating characteristic curve; CI=confidence intervals 
*Patients without a previous history of hypertension 
†Patients with a previous history of hypertension 
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Figure legends 
 
Figure 1. Patient recruitment flow diagram 
 
Figure 2. Post-hoc analyses examining the sensitivity and specificity of the PROOF-BP triaging strategy for 
hypertension, by sub-group. 
 
CI=confidence intervals; ABPM=ambulatory blood pressure monitoring; BMI=body mass index; 
CKD=chronic kidney disease; CVD=cardiovascular disease 
 
Figure 2 data 
Subgroup Total 
population 
Hypertension 
prevalence 
Sensitivity 95% CI Specificity 95% CI 
All patients 887 67.8% 97.2% 95.8% to 98.5% 75.9% 70.9% to 80.8% 
Primary Care 354 61.3% 95.4% 92.6% to 98.2% 78.8% 72.0% to 85.7% 
Secondary Care 533 72.0% 98.2% 96.8% to 99.5% 73.2% 66.0% to 80.3% 
<65 years 649 68.6% 97.3% 95.8% to 98.8% 77.5% 71.7% to 83.2% 
>=65 years 238 65.5% 96.8% 94.0% to 99.6% 72.0% 62.2% to 81.7% 
Women 477 64.4% 95.1% 92.7% to 97.5% 82.9% 77.3% to 88.6% 
Men 410 71.7% 99.3% 98.4% to 100.0% 65.5% 56.9% to 74.2% 
Never/ex-smoker 704 67.2% 97.7% 96.3% to 99.0% 76.6% 71.2% to 82.1% 
Current smoker 124 69.4% 95.3% 90.9% to 99.8% 68.4% 53.6% to 83.2% 
<30kg/m2 478 69.2% 98.2% 96.8% to 99.6% 76.9% 70.1% to 83.7% 
>=30kg/m2 409 66.0% 95.9% 93.6% to 98.3% 74.8% 67.6% to 82.0% 
No hypertension 268 61.2% 95.1% 91.8% to 98.4% 84.6% 77.7% to 91.5% 
Hypertension 619 70.6% 97.9% 96.6% to 99.3% 70.9% 64.3% to 77.5% 
No treatment 348 64.4% 95.1% 92.3% to 97.9% 79.8% 72.8% to 86.9% 
Treatment 539 69.9% 98.4% 97.1% to 99.7% 72.8% 66.0% to 79.7% 
No diabetes 771 68.6% 97.4% 96.0% to 98.7% 75.6% 70.2% to 81.0% 
Diabetes 116 62.1% 95.8% 91.2% to 100.0% 77.3% 64.9% to 89.7% 
No CKD 828 67.3% 96.9% 95.5% to 98.4% 76.8% 71.7% to 81.8% 
CKD 59 74.6% 100.0% 100.0% to 100.0% 60.0% 35.2% to 84.8% 
No CVD 780 68.5% 97.2% 95.8% to 98.6% 76.0% 70.7% to 81.4% 
CVD 107 62.6% 97.0% 92.9% to 100.0% 75.0% 61.6% to 88.4% 
Own monitor 587 73.1% 97.7% 96.2% to 99.1% 73.4% 66.5% to 80.3% 
Monitor provided 300 57.3% 95.9% 93.0% to 98.9% 78.9% 71.8% to 86.0% 
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Figure 3. Proportion of patients correctly classified with hypertension using PROOF-BP strategy, according 
to pre-specified sub-groups. 
 
CI=confidence intervals; ABPM=ambulatory blood pressure monitoring; BMI=body mass index; 
CKD=chronic kidney disease; CVD=cardiovascular disease 
 
Figure 3 data 
Subgroup Total 
population 
Hypertension 
prevalence 
Correctly 
classified 
Correctly 
classified (%) 
95% CI  
All patients 887 67.8% 801 90.3% 88.2% to 92.2% 
Primary Care 354 61.3% 315 89.0% 85.2% to 92.0% 
Secondary Care 533 72.0% 486 91.2% 88.4% to 93.4% 
<65 years 649 68.6% 591 91.1% 88.6% to 93.1% 
>65 years 238 65.5% 210 88.2% 83.4% to 92.0% 
Women 477 64.4% 433 90.8% 87.8% to 93.2% 
Men 410 71.7% 368 89.8% 86.4% to 92.5% 
Never/ex-smoker 704 67.2% 639 90.8% 88.4% to 92.8% 
Current smoker 124 69.4% 108 87.1% 79.9% to 92.4% 
<30kg/m2 478 69.2% 438 91.6% 88.8% to 94.0% 
>30kg/m2 409 66.0% 363 88.8% 85.3% to 91.6% 
No hypertension 268 61.2% 244 91.0% 87.0% to 94.2% 
Hypertension 619 70.6% 557 90.0% 87.3% to 92.2% 
No treatment 348 64.4% 312 89.7% 86.0% to 92.6% 
Treatment 539 69.9% 489 90.7% 88.0% to 93.0% 
No diabetes 771 68.6% 698 90.5% 88.2% to 92.5% 
Diabetes 116 62.1% 103 88.8% 81.6% to 93.9% 
No CKD 828 67.3% 748 90.3% 88.1% to 92.3% 
CKD 59 74.6% 53 89.8% 79.2% to 96.2% 
No CVD 780 68.5% 706 90.5% 88.2% to 92.5% 
CVD 107 62.6% 95 88.8% 81.2% to 94.1% 
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Figure 4. Proportion of patients referred for ABPM using PROOF-BP strategy, according to pre-specified 
sub-groups. 
 
CI=confidence intervals; ABPM=ambulatory blood pressure monitoring; BMI=body mass index; 
CKD=chronic kidney disease; CVD=cardiovascular disease 
 
Figure 4 data 
Subgroup Total 
population 
Hypertension 
prevalence 
Ref for 
ABPM (%) 
Ref for 
ABPM (%) 
95% CI 
All patients 887 67.8% 435 49.0% 45.7% to 52.4% 
Primary Care 354 61.3% 209 59.0% 53.7% to 64.2% 
Secondary Care 533 72.0% 226 42.4% 38.2% to 46.7% 
<65 years 649 68.6% 324 49.9% 46.0% to 53.8% 
>65 years 238 65.5% 111 46.6% 40.2% to 53.2% 
Women 477 64.4% 253 53.0% 48.4% to 57.6% 
Men 410 71.7% 182 44.4% 39.5% to 49.3% 
Never/ex-smoker 704 67.2% 346 49.1% 45.4% to 52.9% 
Current smoker 124 69.4% 57 46.0% 37.0% to 55.1% 
<30kg/m2 478 69.2% 236 49.4% 44.8% to 54.0% 
>30kg/m2 409 66.0% 199 48.7% 43.7% to 53.6% 
No hypertension 268 61.2% 165 61.6% 55.5% to 67.4% 
Hypertension 619 70.6% 270 43.6% 39.7% to 47.6% 
No treatment 348 64.4% 196 56.3% 50.9% to 61.6% 
Treatment 539 69.9% 239 44.3% 40.1% to 48.6% 
No diabetes 771 68.6% 378 49.0% 45.4% to 52.6% 
Diabetes 116 62.1% 57 49.1% 39.7% to 58.6% 
No CKD 828 67.3% 406 49.0% 45.6% to 52.5% 
CKD 59 74.6% 29 49.2% 35.9% to 62.5% 
No CVD 780 68.5% 387 49.6% 46.0% to 53.2% 
CVD 107 62.6% 48 44.9% 35.2% to 54.8% 
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